eXoZymes, Inc. (EXOZ) Stock

eXoZymes, Inc. (EXOZ) is a Healthcare stock trading at $7.38 (as of 2026-08-21), with a market capitalization of $68.45M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

eXoZymes, Inc. operates as a synthetic biochemical company in the United States. The company develops SimplePath, a platform that produces chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds. Its platform also comprises one or more module which consist of one or more enzymes that work together to perform a defined biocatalytic conversion. The company was founded in 2014 and is headquartered in Monrovia, California.

Understand eXoZymes, Inc.: how it makes money

eXoZymes, Inc. develops its SimplePath biocatalysis platform that uses coordinated enzyme modules to produce chemicals, including pharmaceuticals, fuels, materials, food additives, and novel compounds, with monetization tied to producing target compounds at pilot scale and meeting performance targets like conversion, recovery, yield, and purity.

The profit engine is whether eXoZymes can consistently convert feedstocks into target compounds at high performance (reaction conversion, process recovery, isolated yield, and pharma-grade purity) and then scale that performance in pilot production runs, because those chemistry metrics determine commercial feasibility for high-value products.

Business quality (Weak): Financially, the provided data shows a deeply negative operating margin for the 2023-09-30 period, and it does not include gross margin or any segment revenue breakdown, while the available operating KPIs focus on pilot and chemistry performance.

Bull case

  • Strong chemistry performance metrics in the provided dataset: The company reports high Reaction Conversion (99%), Process Recovery (91%), Isolated Yield (90%), and Pharma-Grade Purity (99.6%).
  • Scale-up readiness signals from pilot-focused KPIs: It reports a N-trans-caffeoyltyramine Production Scale-Up Factor of 100.0 alongside Pilot Production Run Volume and production-related metrics.

Bear case

  • Profitability is currently weak based on provided results: The operating margin for 2023-09-30 is -553.7, indicating substantial operating losses in the available data.
  • Limited visibility into commercial traction from the provided facts: There are no reportable segments, no gross margin figure, and no detailed revenue drivers in the provided dataset (revenue_b is shown as 0.0B).
Valuation — source: SEC EDGAR (first-party)
Price$7.38
Market Cap$68.45M
Price / Book18.73
FCF Yield-16.1%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$70069.00
Net Margin-2909.1%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($343524.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMichael Heltzen
Employees31
CountryUS
IPO Date2024-11-13

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Champions Oncology, Inc. (CSBR)
  • INmune Bio, Inc. (INMB)
  • ImageneBio Inc (IMA)
  • MiNK Therapeutics, Inc. (INKT)
  • Instil Bio, Inc. (TIL)
  • Scilex Holding Company (SCLX)
  • Metagenomi, Inc. Common Stock (MGX)
  • Aligos Therapeutics, Inc. (ALGS)
EXOZ earnings history · EXOZ institutional & insider holders · EXOZ KPIs & operating metrics · EXOZ financials · EXOZ investor presentations & press releases · EXOZ SEC filings · EXOZ peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.